Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial
- PMID: 16772623
- DOI: 10.1001/jama.295.22.2605
Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial
Erratum in
- JAMA. 2006 Aug 23;296(8):934
- JAMA. 2007 Nov 7;298(17):2008
Abstract
Context: Antidepressant medication is frequently prescribed for patients with anorexia nervosa.
Objective: To determine whether fluoxetine can promote recovery and prolong time-to-relapse among patients with anorexia nervosa following weight restoration.
Design, setting, and participants: Randomized, double-blind, placebo-controlled trial. From January 2000 until May 2005, 93 patients with anorexia nervosa received intensive inpatient or day-program treatment at the New York State Psychiatric Institute or Toronto General Hospital. Participants regained weight to a minimum body mass index (calculated as weight in kilograms divided by the square of height in meters) of 19.0 and were then eligible to participate in the randomized phase of the trial.
Interventions: Participants were randomly assigned to receive fluoxetine or placebo and were treated for up to 1 year as outpatients in double-blind fashion. All patients also received individual cognitive behavioral therapy.
Main outcome measures: The primary outcome measures were time-to-relapse and the proportion of patients successfully completing 1 year of treatment.
Results: Forty-nine patients were assigned to fluoxetine and 44 to placebo. Similar percentages of patients assigned to fluoxetine and to placebo maintained a body mass index of at least 18.5 and remained in the study for 52 weeks (fluoxetine, 26.5%; placebo, 31.5%; P = .57). In a Cox proportional hazards analysis, with prerandomization body mass index, site, and diagnostic subtype as covariates, there was no significant difference between fluoxetine and placebo in time-to-relapse (hazard ratio, 1.12; 95% CI, 0.65-2.01; P = .64).
Conclusions: This study failed to demonstrate any benefit from fluoxetine in the treatment of patients with anorexia nervosa following weight restoration. Future efforts should focus on developing new models to understand the persistence of this illness and on exploring new psychological and pharmacological treatment approaches.
Trial registration: clinicaltrials.gov Identifier: NCT00288574.
Comment in
-
Fluoxetine treatment of anorexia nervosa: important but disappointing results.JAMA. 2006 Jun 14;295(22):2659-60. doi: 10.1001/jama.295.22.2659. JAMA. 2006. PMID: 16772631 No abstract available.
-
Fluoxetine for treatment of anorexia nervosa.JAMA. 2006 Nov 22;296(20):2439-40; author reply 2440. doi: 10.1001/jama.296.20.2439-c. JAMA. 2006. PMID: 17119138 No abstract available.
Similar articles
-
Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa.Biol Psychiatry. 2001 Apr 1;49(7):644-52. doi: 10.1016/s0006-3223(00)01013-1. Biol Psychiatry. 2001. PMID: 11297722 Clinical Trial.
-
Use of fluoxetine in anorexia nervosa before and after weight restoration.Ann Pharmacother. 2013 Sep;47(9):1201-5. doi: 10.1177/1060028013503127. Ann Pharmacother. 2013. PMID: 24259736 Review.
-
Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls.Psychopharmacol Bull. 1997;33(3):425-31. Psychopharmacol Bull. 1997. PMID: 9550888 Clinical Trial.
-
Fluoxetine for treatment of anorexia nervosa.JAMA. 2006 Nov 22;296(20):2439-40; author reply 2440. doi: 10.1001/jama.296.20.2439-c. JAMA. 2006. PMID: 17119138 No abstract available.
-
Role of fluoxetine in anorexia nervosa.Ann Pharmacother. 2003 Jun;37(6):890-2. doi: 10.1345/aph.1C362. Ann Pharmacother. 2003. PMID: 12773080 Review.
Cited by
-
Intensive Cognitive Behavioral Therapy for Adolescents with Anorexia Nervosa Outcomes before, during and after the COVID-19 Crisis.Nutrients. 2024 May 8;16(10):1411. doi: 10.3390/nu16101411. Nutrients. 2024. PMID: 38794649 Free PMC article.
-
Outcomes of Anorexia Nervosa in a Male Patient Treated With Paroxetine: A Case Report.Cureus. 2024 Apr 22;16(4):e58765. doi: 10.7759/cureus.58765. eCollection 2024 Apr. Cureus. 2024. PMID: 38654963 Free PMC article.
-
Established and emerging treatments for eating disorders.Trends Mol Med. 2024 Apr;30(4):392-402. doi: 10.1016/j.molmed.2024.02.009. Epub 2024 Mar 18. Trends Mol Med. 2024. PMID: 38503683 Free PMC article. Review.
-
Pharmacological Studies in Eating Disorders: A Historical Review.Nutrients. 2024 Feb 22;16(5):594. doi: 10.3390/nu16050594. Nutrients. 2024. PMID: 38474723 Free PMC article. Review.
-
Randomised controlled trial of neurostimulation for symptoms of anorexia nervosa (TRENA study): study protocol.J Eat Disord. 2023 Dec 8;11(1):218. doi: 10.1186/s40337-023-00940-7. J Eat Disord. 2023. PMID: 38066658 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources